CytomX Therapeutics (CTMX) Change in Receivables (2014 - 2026)
CytomX Therapeutics (CTMX) reported Change in Receivables of -$1.4 million for Q1 2026, down 19.18% on a YoY basis from -$1.7 million in Q1 2025, and down 455.99% quarter-over-quarter from $384000.0 in Q4 2025.
CytomX Therapeutics (CTMX) Change in Receivables (2014 - 2026) Analysis & Trends
CytomX Therapeutics has reported Change in Receivables for 13 years, with the latest figure at -$1.4 million in Q1 2026.
- For the quarter ending Q1 2026, Change in Receivables fell 19.18% year-over-year to -$1.4 million; the trailing twelve-month figure through Mar 2026 stood at -$1.3 million (up 88.33% YoY), and the FY2025 full-year result was -$1.1 million, down 231.31% from the prior year.
- Change in Receivables for Q1 2026 stood at -$1.4 million, down from $384000.0 in the prior quarter.
- The five-year high for Change in Receivables was $34.2 million in Q4 2022, with the low at -$34.9 million in Q1 2023.
- Historically, Change in Receivables has averaged -$8470.6 across 5 years, with a median of $232000.0 in 2022.
- Annual changes were most pronounced in 2022 — Change in Receivables jumped 35368.04% — and 2023, when it tumbled 15141.38%.
- CytomX Therapeutics' Change in Receivables stood at $34.2 million in 2022, then tumbled by 97.04% to $1.0 million in 2023, then tumbled by 124.58% to -$249000.0 in 2024, then surged by 254.22% to $384000.0 in 2025, then plunged by 455.99% to -$1.4 million in 2026.
- The last three Change in Receivables figures came in at -$1.4 million (Q1 2026), $384000.0 (Q4 2025), and -$240000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 22,529.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -39.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -4.08 Mn |
| 10 | CytomX Therapeutics | 520.30 Mn | 173.59 Mn | - | -1.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.37 Mn |
| Mar 31, 2026 | -1.37 Mn |
| Dec 31, 2025 | 384,000.00 |
| Dec 31, 2025 | 384,000.00 |
| Sep 30, 2025 | -240,000.00 |
| Sep 30, 2025 | -240,000.00 |
| Jun 30, 2025 | -87,000.00 |
| Jun 30, 2025 | -87,000.00 |
| Mar 31, 2025 | -1.15 Mn |
| Mar 31, 2025 | -1.15 Mn |
| Dec 31, 2024 | -249,000.00 |
| Dec 31, 2024 | -249,000.00 |
| Sep 30, 2024 | 577,000.00 |
| Sep 30, 2024 | 577,000.00 |
| Jun 30, 2024 | -10.40 Mn |
| Jun 30, 2024 | -10.40 Mn |
| Mar 31, 2024 | 9.75 Mn |
| Mar 31, 2024 | 9.75 Mn |
| Dec 31, 2023 | 1.01 Mn |
| Dec 31, 2023 | 1.01 Mn |